联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞

王羽; 范宇平; 胡烨; 黄文强; 滕晓明

doi:10.3969/j.issn.1006-0111.2013.05.010

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞

王羽, 范宇平, 胡烨, 黄文强, 滕晓明

文章导航 > 药学实践与服务 > 2013 > 31(5): 357-358,395

王羽, 范宇平, 胡烨, 黄文强, 滕晓明. 联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞[J]. 药学实践与服务, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010

引用本文:

WANG Yu, FAN Yu-ping, HU Ye, HUANG Wen-qiang, TENG Xiao-ming. Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010

Citation:

WANG Yu, FAN Yu-ping, HU Ye, HUANG Wen-qiang, TENG Xiao-ming. Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010

联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞

doi: 10.3969/j.issn.1006-0111.2013.05.010

同济大学附属第一妇婴保健院生殖医学中心, 上海 200040

Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin

Reproductive Medicine Center, Shanghai First Maternity and Infant Hospital, Tong-ji University School of Medicine, Shanghai 200040, China

摘要: 目的探讨生长激素联合促性腺激素治疗男性低促性腺激素性腺功能低下而引起青春期发育迟滞的临床应用价值。方法回顾性分析2010年6月~2012年5月我院门诊就诊男性青春期发育迟滞患者28例,年龄(15.25±1.11)岁,经明确诊断后予生长激素、卵泡刺激素、人绒毛膜促性腺激素联合治疗。比较治疗前后患者性激素水平、身高、睾丸体积等发育情况变化。结果 28例患者治疗后均得到随访,3个月内随访未出现近期并发症。治疗前后患者身高和睾酮水平均有显著升高(P<0.05);睾丸体积、卵泡刺激素和黄体生成素水平有极显著升高(P<0.01)。结论生长激素、卵泡刺激素、人绒毛膜促性腺激素联合治疗方案对男性低促性腺激素性腺功能低下引起青春期发育迟滞有一定疗效,是临床可行的安全的治疗方案。
- 青春期发育迟滞 /
- 促性腺激素性腺功能低下症 /
- 生长激素 /
- 促性腺激素
Abstract: Objective To evaluate the value and safety of combined therapy of growth hormone and gonadotropin on male delayed puberty caused by hypogonadotropic hypogonadism. Methods A retrospective analysis was undergoing in Shanghai First Maternity and Infant Hospital from 2010 Jun to 2012 May. 28 cases with male delayed puberty caused by hypogonadotropic hypogonadism were enrolled. The average age was (15.25±1.11) years. All the cases were given a combined therapy of human chorionic gonadotrophin, follicle stimulating hormone and growth hormone. After 3 months therapy, the growth condition such as sexual hormone levels, height, and volume of testis were recorded to inspect the treatment effect. Results All 28 cases had a follow-up visit. No short term complications occurred. The height and testosterone level was higher than which before therapy (P<0.05). And the volume of testis, follicle stimulating hormone and luteinizing hormone level were significantly higher than before the therapy. Conclusion Combined therapy of human chorionic gonadotrophin, follicle stimulating hormone and growth hormone could be a safe and effective method to treat male delayed puberty caused by hypogonadotropic hypogonadism.
- male delayed puberty /
- hypogonadotropic hypogonadism /
- growth hHormone /
- gonadotropin

[1]	Silveira LF, MacColl GS, Bouloux PM. Hypogonadotropic hypogonadism[J]. Semin Reprod Med,2002, 20(4):327.
[2]	杨念钦, 王国民. HCG-FSH联合治疗低促性腺激素性性腺功能减退症29例报告[J]. 中国男科学, 2009, 23(12):39.
[3]	狄福松, 崔毓桂, 贾悦. 促性腺激素治疗男性低促性腺激素性性腺功能减退症的疗效评估[J]. 中华内科杂志,2005, 44(11):836.
[4]	Wang GM, O`Shaughnessy PJ, Chubb C, et al. Effects of insulin like growth factor-I on steroidogenic enzyme expression levels in mouse Leydig cells[J]. Endocrinology,2003, 144(11): 5058.
[5]	Warne DW, Decosterd G, Okada H, et al. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin[J]. Fertil Steril, 2009, 92:594.
[6]	Kanzaki M, Morris PL. Growth hormone regulates steroidogenic acute regulatory protein expression and steroidogenesis in Leydig cell progenitors[J]. Endocrinology,1999, 140(4):1681.
[7]	Zheng JX, Liu ZZ, Yang N. Deficiency of growth hormone receptor does not affect male reproduction in dwarf chickens[J]. Poult Sci,2007, 86(1):112.

[1]	潘宇炯, 何志高, 陈石秀, 周桂, 周昕, 郁超. 基于网络药理学和分子对接技术探讨杞贞滋阴合剂治疗性腺功能减退症的作用机制 . 药学实践与服务, 2024, 42(1): 24-31. doi: 10.12206/j.issn.2097-2024.202208111
[2]	赖立勇, 夏天爽, 岳小强, 辛海量. 基于网络药理学的青蒿治疗肾阴虚型糖皮质激素性骨质疏松机制研究 . 药学实践与服务, 2023, 41(11): 672-679. doi: 10.12206/j.issn.2097-2024.202204115
[3]	董雅芬, 王建, 李莉, 李姝姝, 刘河龙, 邱彦. 雌激素对糖尿病大鼠内皮祖细胞功能的影响及其机制研究 . 药学实践与服务, 2022, 40(4): 320-325. doi: 10.12206/j.issn.1006-0111.202106121
[4]	夏天爽, 丁卢颖, 张嘉宝, 李晓瑾, 王果平, 辛海量. 啤酒花及其活性成分黄腐酚抗糖皮质激素性骨质疏松的作用研究 . 药学实践与服务, 2021, 39(3): 221-225. doi: 10.12206/j.issn.1006-0111.202102002
[5]	金薇, 陈继男, 文革生, 高毅. 重组人生长激素治疗青春后期特发性矮小临床观察 . 药学实践与服务, 2012, 30(4): 293-295.
[6]	杨泉海, 王霞. 激素替代疗法及其安全性 . 药学实践与服务, 2003, (5): 263-266.
[7]	陈建明, 叶丽卡, 高申, 毛世瑞, 毕殿洲. 褪黑激素明胶微球剂与溶液剂鼻粘膜给药比较 . 药学实践与服务, 2001, (5): 280-281.
[8]	蒙诚跃, 梁自乾, 王润秀, 张立明, 李德绘, 覃桂萍. 应用人重组生长激素治疗大面积烧伤疗效的观察 . 药学实践与服务, 2001, (6): 326-327.
[9]	张新萍, 贾骏骅. 激素治疗中的药物经济学分析 . 药学实践与服务, 1999, (1): 7-8.
[10]	周建设, 史荣组. 生长激素临床应用进展 . 药学实践与服务, 1997, (3): 143-144,150.
[11]	柳正良, 李名秀, 崔志平. 高效离子对液相色谱法测定促甲状腺激素释放激素(TRH)血药浓度的研究 . 药学实践与服务, 1995, (4): 234-236.
[12]	郑希林. 雌激素的临床应用近况 . 药学实践与服务, 1993, (3): 170-171.
[13]	孙向伟, 周明非. 运动员中雄性激素的滥用 . 药学实践与服务, 1992, (2): 60-61.
[14]	冯春雷. 老药新用治疗急性腺胰炎 . 药学实践与服务, 1992, (2): 54-55.
[15]	石兴华, 徐峰. 糖皮质激素药物的不良又应:国内文献复习 . 药学实践与服务, 1991, (4): 56-58.
[16]	景凡伟, 张紫洞. 雌激素是骨质疏松最佳的治疗 . 药学实践与服务, 1989, (2): 19-19.
[17]	刘月娥, 胡兴钰. 大剂量局部注射皮质激素引起溶骨性骨坏死 . 药学实践与服务, 1986, (4): 33-34.
[18]	王俊华. 雌性激素口腔溃疡药膜通过鉴定 . 药学实践与服务, 1985, (4): 75-75.
[19]	合理用药讨论会会务组. 肾上腺皮质激素的合理应用 . 药学实践与服务, 1985, (1): 9-13.
[20]	R.J.Plumridge. 确保局部用皮质激素的合理使用 . 药学实践与服务, 1984, (4): 29-30.

点击查看大图

计量

文章访问数: 2230
HTML全文浏览量: 271
PDF下载量: 82
被引次数: 0

联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞

doi: 10.3969/j.issn.1006-0111.2013.05.010

同济大学附属第一妇婴保健院生殖医学中心, 上海 200040

收稿日期: 2013-05-03
修回日期: 2013-07-31

关键词:

摘要: 目的探讨生长激素联合促性腺激素治疗男性低促性腺激素性腺功能低下而引起青春期发育迟滞的临床应用价值。方法回顾性分析2010年6月~2012年5月我院门诊就诊男性青春期发育迟滞患者28例,年龄(15.25±1.11)岁,经明确诊断后予生长激素、卵泡刺激素、人绒毛膜促性腺激素联合治疗。比较治疗前后患者性激素水平、身高、睾丸体积等发育情况变化。结果 28例患者治疗后均得到随访,3个月内随访未出现近期并发症。治疗前后患者身高和睾酮水平均有显著升高(P<0.05);睾丸体积、卵泡刺激素和黄体生成素水平有极显著升高(P<0.01)。结论生长激素、卵泡刺激素、人绒毛膜促性腺激素联合治疗方案对男性低促性腺激素性腺功能低下引起青春期发育迟滞有一定疗效,是临床可行的安全的治疗方案。

English Abstract

Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin

Reproductive Medicine Center, Shanghai First Maternity and Infant Hospital, Tong-ji University School of Medicine, Shanghai 200040, China

Received Date: 2013-05-03
Rev Recd Date: 2013-07-31

Keywords:

Abstract: Objective To evaluate the value and safety of combined therapy of growth hormone and gonadotropin on male delayed puberty caused by hypogonadotropic hypogonadism. Methods A retrospective analysis was undergoing in Shanghai First Maternity and Infant Hospital from 2010 Jun to 2012 May. 28 cases with male delayed puberty caused by hypogonadotropic hypogonadism were enrolled. The average age was (15.25±1.11) years. All the cases were given a combined therapy of human chorionic gonadotrophin, follicle stimulating hormone and growth hormone. After 3 months therapy, the growth condition such as sexual hormone levels, height, and volume of testis were recorded to inspect the treatment effect. Results All 28 cases had a follow-up visit. No short term complications occurred. The height and testosterone level was higher than which before therapy (P<0.05). And the volume of testis, follicle stimulating hormone and luteinizing hormone level were significantly higher than before the therapy. Conclusion Combined therapy of human chorionic gonadotrophin, follicle stimulating hormone and growth hormone could be a safe and effective method to treat male delayed puberty caused by hypogonadotropic hypogonadism.

引用本文:

Citation:

WANG Yu, FAN Yu-ping, HU Ye, HUANG Wen-qiang, TENG Xiao-ming. Therapy on male delayed puberty caused by hypogonadotropic hypogonadism by combination of growth hormone and gonadotropin[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010